Search clinical trials for: Nepafenac Ophthalmic Suspension, 0.1%

Total 540 results

Alcon Research

Completed

Confirmatory Study Nepafenac 0.3%

Cataract

United States
Alcon Research

Completed

Nepafenac 0.3% Two Study

Cataract

United States
Toyos Clinic
Bausch & Lomb Incorporated

Completed

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%

Inflammation | Pseudophakia
Alcon Research

Terminated

Macular Edema Incidence/Severity Reduction With Nevanac

Diabetic Retinopathy

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Inflammation and Pain Following Ocular Surgery

United States
Alcon Research

Completed

Nepafenac Compared to Placebo for Ocular Pain and Inflammation

Cataract

China
Melissa Toyos
Bausch & Lomb Incorporated

Completed

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery (QD)

Inflammation | Cataract | Retinal Edema

United States
Santen Inc.
ActualEyes Inc.

Recruiting

A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD) (PHANTOM)

Fuchs Endothelial Corneal Dystrophy

United States
Alcon Research

Completed

Nevanac 3-Month Safety Study With QID Dosing

Cataract

United States
Reata, a wholly owned subsidiary of Biogen
AbbVie

Completed

RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD

Ocular Inflammation | Ocular Pain | Corneal Endothelial Cell Loss | Cataract Surgery

United States
Alcon Research

Withdrawn

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Bacterial Conjunctivitis
Alcon Research

Completed

Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

Cataract

United States
University of Trieste

Completed

PGE2 Levels in Patient Treated With NSAIDs

Ocular Inflammation

Italy
Alcon Research

Completed

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients

Macular Edema
Bausch & Lomb Incorporated

Completed

Study to Assess the Safety and Efficacy of BOL-303242-X Ophthalmic Suspension in Dry Eye Syndrome

Dry Eye Syndrome

United States
University Hospital of Patras

Completed

Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections

Pain

Greece
Alcon Research

Completed

Nepafenac Once Daily for Macular Edema - Study 1

Cataract | Non-Proliferative Diabetic Retinopathy
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Corneal Scar

United States
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Alcon Research

Completed

Nepafenac Once Daily for Macular Edema - Study 2

Cataract | Non-Proliferative Diabetic Retinopathy
Santen Inc.

Completed

A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye Disease

United States
Aldeyra Therapeutics, Inc.

Completed

A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome

Dry Eye Syndromes

United States
Cornea Consultants Of Nashville
Bausch & Lomb Incorporated; SCRI Development Innovations, LLC

Terminated

A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers. (Eye02)

Corneal Ulcers

United States
University Hospital of Patras

Completed

Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections

Pain

Greece
Sheba Medical Center

Unknown

Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy

Glaucoma, Angle-Closure | Glaucoma, Closed-Angle | Glaucoma, Narrow-Angle

Israel
Santen Inc.

Completed

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia (OPSIS)

Presbyopia

United States
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Neurotrophic Keratitis

United States, Canada
Santen Inc.

Completed

Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye Disease

Dry Eye

United States
Betaliq, Inc.
Trial Runners, LLC; Summit Analytical, LLC

Completed

Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

United States
Aldeyra Therapeutics, Inc.
ORA, Inc.

Completed

A Study of ADX-102 in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Allysta Pharmaceutical

Completed

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

Dry Eye Disease

United States
Azura Ophthalmics
ORA, Inc.

Not yet recruiting

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Dry Eye Disease

United States
Jaeb Center for Health Research
National Eye Institute (NEI)

Completed

NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)

Diabetic Macular Edema

United States
Aldeyra Therapeutics, Inc.

Completed

A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis

Allergic Conjunctivitis | Seasonal Allergies

Canada
Kala Pharmaceuticals, Inc.

Completed

Safety and Efficacy of KPI-121 in Subjects With DED (STRIDE 3)

Kerato Conjunctivitis Sicca

United States
Allergan

Completed

A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin

Ocular Hypertension

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) (DROPS-2)

Chronic Graft-versus-host Disease

United States
L.V. Prasad Eye Institute
Allergan

Recruiting

CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops

Congenital Hereditary Endothelial Dystrophy of Cornea

India
Rigel Pharmaceuticals

Completed

To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca (DROPS)

Keratoconjunctivitis Sicca

United States
Rigel Pharmaceuticals

Completed

A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease

Keratoconjunctivitis Sicca

United States
Alcon Research

Completed

Adjunctive Study of AL-37807 Ophthalmic Suspension

Ocular Hypertension | Open-Angle Glaucoma

United States
Alcon Research

Completed

6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma
Topivert Pharma Ltd

Completed

Study of TOP1630 for Dry Eye Syndrome (THEIA-1)

Dry Eye Syndrome

United States
Johns Hopkins University

Completed

Study of Ocular Penetration of Topically Administered Fluoroquinolones

Cataract Extraction

United States
Alcon Research

Completed

Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Terminated

Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination

Ocular Hypertension | Open-Angle Glaucoma
Alcon Research

Completed

Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-Angle Glaucoma

3

Subscribe